Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 242.85 Billion KRW | 5.19% |
| 2022 | 230.88 Billion KRW | 43.71% |
| 2021 | 160.65 Billion KRW | 25.41% |
| 2020 | 128.1 Billion KRW | 5.35% |
| 2019 | 121.6 Billion KRW | 32.37% |
| 2018 | 91.86 Billion KRW | 8.96% |
| 2017 | 84.3 Billion KRW | 75.19% |
| 2016 | 48.12 Billion KRW | 7.18% |
| 2015 | 44.9 Billion KRW | -15.08% |
| 2014 | 52.87 Billion KRW | 15.75% |
| 2013 | 45.68 Billion KRW | -5.07% |
| 2012 | 48.12 Billion KRW | -11.86% |
| 2011 | 54.59 Billion KRW | -3.44% |
| 2010 | 56.54 Billion KRW | -4.54% |
| 2009 | 59.23 Billion KRW | 0.36% |
| 2008 | 59.02 Billion KRW | 94.41% |
| 2007 | 30.35 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 205.1 Billion KRW | -4.81% |
| 2024 Q1 | 215.46 Billion KRW | -11.28% |
| 2023 FY | 242.85 Billion KRW | 5.19% |
| 2023 Q1 | 230.59 Billion KRW | -0.12% |
| 2023 Q4 | 242.85 Billion KRW | -3.05% |
| 2023 Q3 | 250.49 Billion KRW | 4.63% |
| 2023 Q2 | 239.41 Billion KRW | 3.82% |
| 2022 Q2 | 202.26 Billion KRW | 14.74% |
| 2022 Q4 | 230.88 Billion KRW | 9.62% |
| 2022 Q3 | 210.61 Billion KRW | 4.13% |
| 2022 Q1 | 176.27 Billion KRW | 9.72% |
| 2022 FY | 230.88 Billion KRW | 43.71% |
| 2021 Q3 | 158.45 Billion KRW | 0.07% |
| 2021 FY | 160.65 Billion KRW | 25.41% |
| 2021 Q4 | 160.65 Billion KRW | 1.39% |
| 2021 Q1 | 131.25 Billion KRW | 2.46% |
| 2021 Q2 | 158.34 Billion KRW | 20.64% |
| 2020 Q4 | 128.1 Billion KRW | 5.74% |
| 2020 Q1 | 119.78 Billion KRW | -1.5% |
| 2020 Q2 | 122.42 Billion KRW | 2.21% |
| 2020 Q3 | 121.15 Billion KRW | -1.04% |
| 2020 FY | 128.1 Billion KRW | 5.35% |
| 2019 FY | 121.6 Billion KRW | 32.37% |
| 2019 Q4 | 121.6 Billion KRW | 2.34% |
| 2019 Q2 | 91.01 Billion KRW | 0.36% |
| 2019 Q1 | 90.69 Billion KRW | -1.28% |
| 2019 Q3 | 118.82 Billion KRW | 30.55% |
| 2018 Q3 | 90.53 Billion KRW | -0.1% |
| 2018 FY | 91.86 Billion KRW | 8.96% |
| 2018 Q1 | 86.35 Billion KRW | 2.43% |
| 2018 Q2 | 90.62 Billion KRW | 4.94% |
| 2018 Q4 | 91.86 Billion KRW | 1.47% |
| 2017 Q3 | 81.95 Billion KRW | 5.19% |
| 2017 FY | 84.3 Billion KRW | 75.19% |
| 2017 Q1 | 43.92 Billion KRW | -8.73% |
| 2017 Q4 | 84.3 Billion KRW | 2.88% |
| 2017 Q2 | 77.9 Billion KRW | 77.36% |
| 2016 FY | 48.12 Billion KRW | 7.18% |
| 2016 Q4 | 48.12 Billion KRW | -2.23% |
| 2016 Q3 | 49.22 Billion KRW | 3.03% |
| 2016 Q2 | 47.77 Billion KRW | 7.2% |
| 2016 Q1 | 44.56 Billion KRW | -0.75% |
| 2015 Q3 | 44.66 Billion KRW | -11.57% |
| 2015 Q1 | 53.07 Billion KRW | 0.38% |
| 2015 Q2 | 50.51 Billion KRW | -4.83% |
| 2015 FY | 44.9 Billion KRW | -15.08% |
| 2015 Q4 | 44.9 Billion KRW | 0.52% |
| 2014 Q2 | 50.46 Billion KRW | 6.12% |
| 2014 Q1 | 47.55 Billion KRW | 4.11% |
| 2014 FY | 52.87 Billion KRW | 15.75% |
| 2014 Q4 | 52.87 Billion KRW | 1.56% |
| 2014 Q3 | 52.06 Billion KRW | 3.15% |
| 2013 Q1 | 46.69 Billion KRW | -2.97% |
| 2013 FY | 45.68 Billion KRW | -5.07% |
| 2013 Q3 | 45.68 Billion KRW | -0.39% |
| 2013 Q2 | 45.86 Billion KRW | -1.79% |
| 2013 Q4 | 45.68 Billion KRW | 0.0% |
| 2012 Q4 | 48.12 Billion KRW | 0.0% |
| 2012 FY | 48.12 Billion KRW | -11.86% |
| 2012 Q1 | 49.73 Billion KRW | 0.0% |
| 2011 Q2 | 57.6 Billion KRW | 1.2% |
| 2011 Q3 | 53.62 Billion KRW | -6.91% |
| 2011 FY | 54.59 Billion KRW | -3.44% |
| 2011 Q1 | 56.91 Billion KRW | 0.66% |
| 2010 Q2 | 53.08 Billion KRW | 14.22% |
| 2010 FY | 56.54 Billion KRW | -4.54% |
| 2010 Q1 | 46.47 Billion KRW | -21.54% |
| 2010 Q4 | 56.54 Billion KRW | 2.82% |
| 2010 Q3 | 54.99 Billion KRW | 3.6% |
| 2009 Q2 | 61.22 Billion KRW | -1.76% |
| 2009 Q3 | 62.17 Billion KRW | 1.56% |
| 2009 Q1 | 62.31 Billion KRW | 5.59% |
| 2009 FY | 59.23 Billion KRW | 0.36% |
| 2009 Q4 | 59.23 Billion KRW | -4.73% |
| 2008 FY | 59.02 Billion KRW | 94.41% |
| 2008 Q2 | 50.28 Billion KRW | 11.11% |
| 2008 Q4 | 59.02 Billion KRW | -2.44% |
| 2008 Q3 | 60.49 Billion KRW | 20.31% |
| 2008 Q1 | 45.25 Billion KRW | 49.06% |
| 2007 Q3 | 30.93 Billion KRW | -9.52% |
| 2007 Q4 | 30.35 Billion KRW | -1.86% |
| 2007 FY | 30.35 Billion KRW | 0.0% |
| 2007 Q1 | 32.26 Billion KRW | 0.0% |
| 2007 Q2 | 34.18 Billion KRW | 5.96% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -211.918% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 73.881% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 65.655% |
| HANDOK Inc. | 449.7 Billion KRW | 45.998% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -183.473% |
| Yuhan Corporation | 712.33 Billion KRW | 65.908% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 61.569% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1427.906% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 71.49% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -353.688% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -17.961% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -223.067% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -64.318% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -244.955% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -211.918% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -566.514% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 3.304% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -10.035% |
| JW Holdings Corporation | 827.51 Billion KRW | 70.653% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 44.427% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 58.614% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 36.024% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -206.24% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -247.093% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 26.474% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -211.918% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 50.44% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 71.696% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 36.024% |
| Yuhan Corporation | 712.33 Billion KRW | 65.908% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 49.174% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -77.306% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 52.996% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 36.024% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -57.149% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -169.94% |
| CKD Bio Corp. | 170.76 Billion KRW | -42.218% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 0.362% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -54.039% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -464.522% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -206.24% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 61.605% |
| Boryung Corporation | 373.1 Billion KRW | 34.911% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -16.645% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -17.961% |
| JW Lifescience Corporation | 96.44 Billion KRW | -151.809% |